Resmed (RSMDF) Total Liabilities (2010 - 2026)

Resmed has reported Total Liabilities for 17 years, with the latest figure at $2.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 13.45% year-over-year to $2.3 billion; the trailing twelve-month figure through Mar 2026 stood at $2.3 billion (up 13.45% YoY), and the FY2025 full-year result was $2.2 billion, up 9.87% from the prior year.
• Total Liabilities for Q1 2026 stood at $2.3 billion, up from $2.2 billion in the prior quarter.
• The five-year high for Total Liabilities was $2.9 billion in Q4 2022, with the low at $1.6 billion in Q1 2022.
• Historically, Total Liabilities has averaged $2.2 billion across 5 years, with a median of $2.2 billion in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 84.91% — and 2024, when it declined 23.4%.
• Resmed's Total Liabilities stood at $2.9 billion in 2022, then declined by 17.52% to $2.4 billion in 2023, then declined by 22.07% to $1.9 billion in 2024, then rose by 15.58% to $2.2 billion in 2025, then increased by 5.03% to $2.3 billion in 2026.
• The last three Total Liabilities figures came in at $2.3 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.